Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system
Joseph A. Lewnard, John M. McLaughlin, Deborah E. Malden, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 25

Showing 25 citing articles:

Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 48, pp. 1531-1537
Open Access | Times Cited: 84
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 807-816
Open Access | Times Cited: 70
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Jennifer Hammond, Robert J. Fountaine, Carla Yunis, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1186-1195
Open Access | Times Cited: 61
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 46
Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
American Journal of Transplantation (2023) Vol. 23, Iss. 1, pp. 150-155
Open Access | Times Cited: 31
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
Chris A. Gentry, Phoi N Nguyen, Sharanjeet K. Thind, et al.
Journal of Infection (2023) Vol. 86, Iss. 3, pp. 248-255
Open Access | Times Cited: 15
The prevalence of SARS-CoV-2 infection and other public health outcomes during the BA.2/BA.2.12.1 surge, New York City, April–May 2022
Saba A Qasmieh, McKaylee Robertson, Chloe A. Teasdale, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 12
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Kathiaja Miranda Souza, G. Carrasco, Robin Rojas-Cortés, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0284006-e0284006
Open Access | Times Cited: 12
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 108-110
Open Access | Times Cited: 3
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
Hannah A. Blair
Drugs & Therapy Perspectives (2022) Vol. 39, Iss. 2, pp. 41-47
Open Access | Times Cited: 12
Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
Ye Qiu, Hao Wen, Haoru Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Update on COVID-19 Therapy in Pediatric Age
Susanna Esposito, Giovanni Autore, Alberto Argentiero, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1512-1512
Open Access | Times Cited: 11
Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
Carlos King Ho Wong, Kristy T. K. Lau, GM Leung
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 639-640
Open Access | Times Cited: 6
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
Clinical characteristics and outcomes of children with COVID-19 in pediatric intensive care units during the Omicron wave in Taiwan
Jeng‐Hung Wu, Ching-Chia Wang, Frank Leigh Lu, et al.
Journal of the Formosan Medical Association (2024)
Open Access | Times Cited: 1
The effect of nirmatrelvir-ritonavir on short- and long-term adverse outcomes from COVID-19 among patients with kidney disease: A propensity-score matched study
Ian A. Strohbehn, Tianqi Ouyang, Meghan Lee, et al.
Open Forum Infectious Diseases (2024)
Open Access | Times Cited: 1
Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis
Chienhsiu Huang, Sufang Kuo, Lichen Lin
童綜合醫學雜誌 (2024) Vol. 18, Iss. Suppl 1, pp. S35-S47
Open Access
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID‐19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta‐Analysis
Kristy T. K. Lau, Xi Xiong, Carlos King Ho Wong, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 12
Open Access
National survey study of nirmatrelvir-ritonavir prescribing processes and access barriers during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron surge of the coronavirus disease 2019 (COVID-19) pandemic
Rebecca Wang, Michael S. Calderwood, Craig P. Worby, et al.
Infection Control and Hospital Epidemiology (2023) Vol. 44, Iss. 11, pp. 1881-1883
Closed Access | Times Cited: 1
Antivirals for the treatment of mild and moderate COVID-19 in South Africa
Rubeshan Perumal, Vinny Naidoo, S. Govender, et al.
South African Medical Journal (2023) Vol. 113, Iss. 12, pp. 33-33
Open Access | Times Cited: 1
Estimated Impact of Oral Nirmatrelvir;Ritonavir on Reductions in Hospitalizations and Associated Costs within High-Risk COVID-19 Patients in the US
Rickard Sandin, Cale Harrison, Florin Draica, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 2
REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUÉBEC, CANADA
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Effectiveness of Nirmatrelvir-Ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Kathiaja Miranda Souza, G. Carrasco, Robin Rojas-Cortés, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Receipt of anti-SARS-CoV-2 pharmacotherapies among non-hospitalized U.S. Veterans with COVID-19, January 2022 to January 2023
Lei Yan, Elani Streja, Yuli Li, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top